IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.493
AS - Asia 1.650
EU - Europa 1.512
SA - Sud America 412
AF - Africa 375
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.361
SG - Singapore 771
CN - Cina 615
IE - Irlanda 437
IT - Italia 410
BR - Brasile 354
CI - Costa d'Avorio 298
UA - Ucraina 192
RU - Federazione Russa 123
CA - Canada 118
DE - Germania 94
VN - Vietnam 74
GB - Regno Unito 55
SN - Senegal 54
IN - India 53
FR - Francia 37
KR - Corea 37
SE - Svezia 36
FI - Finlandia 25
BD - Bangladesh 19
AR - Argentina 18
NL - Olanda 18
CH - Svizzera 16
PL - Polonia 16
UZ - Uzbekistan 14
EC - Ecuador 11
AT - Austria 10
MX - Messico 10
IQ - Iraq 9
HK - Hong Kong 8
VE - Venezuela 8
JP - Giappone 7
LB - Libano 7
PK - Pakistan 7
TR - Turchia 7
ZA - Sudafrica 7
AU - Australia 6
CO - Colombia 6
LT - Lituania 6
BE - Belgio 5
CZ - Repubblica Ceca 5
GR - Grecia 5
HR - Croazia 5
SA - Arabia Saudita 5
ES - Italia 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
PY - Paraguay 4
TN - Tunisia 4
HU - Ungheria 3
KE - Kenya 3
UY - Uruguay 3
BO - Bolivia 2
CL - Cile 2
DZ - Algeria 2
IL - Israele 2
LK - Sri Lanka 2
MA - Marocco 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BT - Bhutan 1
BY - Bielorussia 1
CR - Costa Rica 1
EG - Egitto 1
EU - Europa 1
GT - Guatemala 1
ID - Indonesia 1
IR - Iran 1
JO - Giordania 1
KH - Cambogia 1
KI - Kiribati 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
PW - Palau 1
SV - El Salvador 1
Totale 8.451
Salva come PNG Salva come JPEG
Città #
Dallas 844
Santa Clara 655
Chandler 562
Singapore 465
Dublin 435
Abidjan 298
Chicago 199
Jacksonville 196
Boardman 173
Ashburn 168
Cambridge 119
Lawrence 119
Andover 116
Houston 109
Nanjing 101
Beijing 85
Catania 78
Toronto 78
Hefei 75
Civitanova Marche 63
Des Moines 57
Los Angeles 56
Dakar 54
Wilmington 49
Seoul 37
Nanchang 34
Grafing 33
Shenyang 32
Bremen 31
San Mateo 29
Saint Petersburg 28
Ottawa 27
Dong Ket 26
Council Bluffs 25
São Paulo 25
Hebei 22
The Dalles 22
Changsha 21
Columbus 21
Jiaxing 19
Lappeenranta 18
San Francisco 17
Moscow 16
Washington 16
Hanoi 15
Tianjin 15
Bari 12
Siracusa 11
Ho Chi Minh City 10
London 10
Pune 10
Seattle 10
Belo Horizonte 9
Chennai 9
Jinan 9
New York 9
Norwalk 9
Padova 9
Rio de Janeiro 9
Zhengzhou 9
Kunming 8
Mumbai 8
Ningbo 8
Phoenix 8
Warsaw 8
Ann Arbor 7
Brasília 7
Den Haag 7
Porto Alegre 7
Rome 7
Zola Predosa 7
Amsterdam 6
Brooklyn 6
Edinburgh 6
Goiânia 6
Guangzhou 6
Guarulhos 6
Helsinki 6
Messina 6
Quito 6
Redwood City 6
Tokyo 6
Denver 5
Frankfurt Am Main 5
Hong Kong 5
Juiz de Fora 5
Manchester 5
Mascalucia 5
Montreal 5
Naples 5
Orem 5
Salvador 5
Sydney 5
Tashkent 5
Zagreb 5
Baghdad 4
Brussels 4
Charlotte 4
Civitavecchia 4
Dhaka 4
Totale 6.051
Salva come PNG Salva come JPEG
Nome #
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 141
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 132
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 131
Management of dysphagia in multiple sclerosis: current best practice 125
Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome 112
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 109
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 102
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 101
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. 100
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 99
An update on the safety of treating relapsing-remitting multiple sclerosis 98
Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS 95
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 93
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 92
Can new chemical therapies improve the management of multiple sclerosis in children? 91
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 91
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 90
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 88
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study 88
Association between dietary intake and function in amyotrophic lateral sclerosis 88
Approccio clinico e possibilità di trattamento nella SLA 88
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 86
Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review 85
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 85
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 84
CCSVI and MS. A population-based case-control study in Catania, Sicily. 84
Palliative care in progressive multiple sclerosis 83
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis 83
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 83
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 82
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 82
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 81
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 81
An update on the pharmacological management of pain in patients with multiple sclerosis 81
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 79
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 79
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 78
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 78
Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study 77
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 77
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 76
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 76
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. 76
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 76
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 75
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 74
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 73
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 73
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 72
Treatment options of cognitive impairment in multiple sclerosis 71
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 71
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 71
Pharmacoeconomics of synthetic therapies for multiple sclerosis 71
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 71
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 71
The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study 69
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 68
Detrimental effects of cyclophosphamide on seminal cells in men whith MS 67
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 67
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 67
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 67
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 67
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 67
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 66
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 65
Primary cerebral vasculitis 65
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 65
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 65
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 64
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 63
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 63
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 62
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 62
Cognitive-motor dual-task interference:A systematic review of neural correlates 61
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 61
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 60
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 59
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question 59
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 58
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 58
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 58
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 58
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 58
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 57
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 57
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 57
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 56
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 55
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 55
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 54
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study 54
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 53
The effects of different cognitive and motor tasks on the dual task cost of walking in multiple sclerosis: a case-control study 53
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 53
Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates 51
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 51
Prevalence of patient-reported disphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire) 51
Prevalence of pain in multiple sclerosis: a multicenter italian study 51
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 51
Serum and CSF N-acetyl aspartate Levels differ in multiple sclerosis and neuromyelitis optica. 51
Totale 7.478
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021389 0 0 0 9 166 9 30 5 65 15 47 43
2021/2022799 79 130 15 8 125 4 123 22 52 5 41 195
2022/20231.609 128 84 30 164 154 282 4 281 386 6 68 22
2023/2024704 34 182 37 19 23 119 21 64 4 31 117 53
2024/20252.438 30 366 150 128 493 354 75 94 198 231 172 147
2025/20261.773 305 214 981 273 0 0 0 0 0 0 0 0
Totale 8.685